Amgen agreed last month to pay $24.9 million to resolve claims it gave kickbacks to increase sales of its anemia drug Aranesp. Missouri was among several states that accused Amgen of a scheme aimed at inducing nursing home professionals to dispense Aranesp over competing drugs. Missouri's share is $603,493.
Aranesp is one of Amgen's biggest-selling drugs, though sales have fallen sharply since 2007 because of a series of safety problems and restrictions on its use.
In December, Amgen agreed to pay $762 million to resolve federal litigation accusing it of marketing Aranesp for unapproved uses.